Warner Chilcott Plc offers potential acquirers the chance to buy a company that throws off more cash from selling contraceptives and colitis treatments than any specialty drugmaker in the world.
Actavis Inc., the largest U.S. maker of generic drugs by market value, agreed to acquire Warner Chilcott Plc for about $5 billion excluding net debt in a deal to expand in women’s health and urology.
Actavis Inc., the largest U.S. maker of generic drugs by market value, said it’s in “early stage discussions” to buy Warner Chilcott Plc, the drugmaker that unsuccessfully pursued a sale last year.
Mylan Inc. was sued by a unit of Warner Chilcott Plc for infringing a U.S. patent with plans to market low-cost copies of the oral contraceptive Generess FE.
Actavis Inc. agreed to sell assets covering four generic drugs in a settlement with U.S. regulators that clears the way for its $8.5 billion acquisition of Warner Chilcott Plc.
Mylan Inc. said it began selling a generic version of the antibiotic Doryx today after a judge ruled it didn’t infringe a patent held by Warner Chilcott Plc.